MedPath
HSA Approval

APO-AMOXI FOR ORAL SUSPENSION 125 mg/5 ml

SIN01664P

APO-AMOXI FOR ORAL SUSPENSION 125 mg/5 ml

APO-AMOXI FOR ORAL SUSPENSION 125 mg/5 ml

June 7, 1988

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

POWDER, FOR SUSPENSION

ORAL

Medical Information

J01CA04

amoxicillin

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

APO-BIOTICS LIMITED

Active Ingredients

AMOXYCILLIN TRIHYDRATE EQV AMOXYCILLIN

125 mg/5 ml

Amoxicillin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-AMOXI FOR ORAL SUSPENSION 125 mg/5 ml - HSA Approval | MedPath